Horizon Discovery
- Sector:
- Pharmaceuticals & Biotechnology
- Exit type:
- Placement of blocks of shares on AIM
Most Recent Exit | In Price/Share | Average Out Price/Share |
2016 | £0.87 | £1.59 |
Horizon Discovery is a world leader in the application of gene editing technologies, which are used for research into, and treatment of, genetically-based diseases.
Calculus Capital exited its holding in 2016, via a placement of shares on the AIM. The average exit multiple for sale of the shares was 1.82x, constituting a tax free return of over 160%, when factoring in initial investor income tax relief of 30%. The investment was held for 3 years, 3 months.
Past performance is not a guide to future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future.